​Trienix Pharma is an emerging biopharmaceutical company advancing a new class of synthetic resolution modulators inspired by specialized pro-resolving mediators (SPMs). Rooted in innovative lipid chemistry and receptor biology, Trienix Pharma is the first to rationally design and synthesize analogs of PDX, a triene-diol derived from the omega-3 fatty acid docosahexaenoic acid (DHA) with potent immunoresolving properties. The company’s proprietary platform focuses on harnessing resolution biology to address chronic inflammation and fibrosis—hallmarks of diseases such as metabolic dysfunction-associated steatotic liver disease (MASLD), acute and chronic pain, and viral infections. Trienix’s lead program is a first-in-class GPR37-targeting small molecule with dual potential as a non-opioid analgesic and as a disease-modifying agent in MASLD.

 

The team includes multidisciplinary experts in medicinal chemistry, pharmacology, and translational biology, supported by a growing network of academic and clinical collaborators. With a strong IP portfolio and preclinical proof-of-concept in animal models, Trienix Pharma is positioned to become a key player in the next wave of anti-inflammatory therapeutics that move beyond immunosuppression to restore tissue homeostasis and function.